Research programme: proteolytic bacterial enzymes - Hansa Medical

Drug Profile

Research programme: proteolytic bacterial enzymes - Hansa Medical

Alternative Names: Endoglycosidase of Streptococcus pyogenes; EndoS; Second generation IdeS; Second generation Ig-G-degrading enzyme of Streptococcus pyogenes

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hansa Medical AB
  • Class Anti-inflammatories; Antineoplastics; Bacterial proteins; Enzymes; Immunotherapies
  • Mechanism of Action Immunoglobulin modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Transplant rejection
  • No development reported Autoimmune disorders
  • Discontinued Rheumatoid arthritis; Streptococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Sweden (Parenteral)
  • 10 Apr 2015 Early research in Transplant rejection (Prevention) in Sweden (Parenteral)
  • 05 Feb 2013 The Swedish Medical Products Agency approves clinical trial application for IdeS in Healthy volunteers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top